AvenCell Therapeutics (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- June 09, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $112,000,000
Company Info
- Company Description
- AvenCell Therapeutics is a clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, targeting difficult-to-treat cancers such as acute myeloid leukemia (AML). The company aims to create allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct for complete control and target redirection of T cells post-infusion.
- Market
- Cell Therapy
- Location
- Watertown, Massachusetts, USA
- Coinvestors
- Novo Holdings, F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, NYBC Ventures, Blackstone Life Sciences